July 01, 2025 a 08:38 am
DGX: Analysts Ratings - Quest Diagnostics Incorporated
Quest Diagnostics Incorporated (DGX) has shown a stable market presence with a majority of analysts recommending a 'Hold'. Over recent months, recommendations have primarily circled around 'Hold' and 'Buy', signaling a cautious optimism from the analyst community. The diagnostic services sector continues to demand attention amidst evolving healthcare needs.
Historical Stock Grades
| Recommendation | Number | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 8 | |
| Hold | 10 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
The sentiment towards DGX has seen a slight shift. While 'Buy' recommendations remain stable, there is a noticeable increase in 'Hold' ratings, reflecting a potential wait-and-see approach. The overall rating count has remained fairly constant, indicating steady interest and attention from analysts.
- A decrease in 'Strong Buy' recommendations over the past year.
- 'Hold' has become the predominant recommendation, suggesting cautious outlooks.
Percentage Trends
Over the past several months, the emphasis has shifted more towards 'Hold', decreasing the relative percentage of 'Buy'. The shift indicates a more conservative sentiment among analysts, possibly due to market conditions or company-specific challenges.
- January 2025 saw a peak in 'Buy' ratings at 37.5%, which contracted to 33% in June.
- 'Hold' ratings increased from 37.5% in January 2025 to 41.67% in June.
- The consistent 'Strong Sell' presence highlights mixed confidence levels from various analysts.
Latest Analyst Recommendations
The latest analyst recommendations for DGX showcase a stable perspective with no significant deviations from prior sentiments. The most recent ratings suggest analysts are maintaining their positions, reflecting an absence of substantial new market signals.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-06 | Neutral | Neutral | JP Morgan |
| 2025-04-28 | Neutral | Neutral | Piper Sandler |
| 2025-04-23 | Equal Weight | Equal Weight | Barclays |
| 2025-04-23 | Hold | Hold | Truist Securities |
| 2025-04-23 | Outperform | Outperform | Baird |
Analyst Recommendations with Change of Opinion
Recent changes in analyst opinions hint at strategic re-evaluations rather than knee-jerk reactions. Upgrades and downgrades suggest a nuanced view of DGX's market standing as opposed to widespread agreement on potential.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-03-04 | Neutral | Buy | Citigroup |
| 2025-01-06 | Outperform | Market Perform | Leerink Partners |
| 2024-12-17 | Overweight | Equal Weight | Morgan Stanley |
| 2024-10-23 | Outperform | Neutral | Baird |
| 2024-07-10 | Buy | Neutral | Citigroup |
Interpretation
With the current data, there are indications of market stability with a slight inclination towards caution. The consistency in 'Hold' recommendations implies maintained interest but a probable uncertainty in growth prospects. The shifts between 'Strong Buy' and 'Hold' suggest adjustments to market dynamics or operational developments within Quest Diagnostics. These trends highlight a cautious but open-minded view from analysts as they assess future pathways.
Conclusion
The recent analysis of Quest Diagnostics Incorporated (DGX) reflects a market characterized by stability and cautious optimism. While there are fewer 'Strong Buy' recommendations, the prevailing 'Hold' sentiments suggest a steadiness within the sector. The noted rating changes, upgrades, and downgrades indicate a balanced reevaluation by analysts responding to market cues and operational performance. Investors should continue to monitor developments closely, as maintaining a grip on both risk and opportunity in this dynamic environment is crucial.